Novartis AG at JPMorgan Healthcare Conference Transcript
Thanks. Welcome to the 38th Healthcare Conference at JPMorgan. I'm Richard Vosser, European Pharma Analyst at JPMorgan. It's my pleasure to introduce Vas Narasimhan, CEO of Novartis, and welcome him to the conference.
Before I hand over to Vas, I'd just point out that the breakout session is in the Borgia Room after this presentation. Vas, welcome.
Thank you, Richard, and it's great to be here, great to open the year, as always, at JPMorgan. I'd like to give some perspectives on the journey Novartis has been on over the last couple of years. I'm now entering my third year as CEO, and I think we're making progress on the strategy we set out to become the leading medicines company powered by advanced therapy platforms and data science. Now when you think about what we set out, we set out to focus the company and focus the company around our core of Innovative Medicines while looking to accelerate certain geographies where we thought we could
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
